SUPPLEMENTAL DIGITAL CONTENT 6

HIV-1 RNA <40 copies/mL at Week 96 (Snapshot analysis, N=272) by subgroup.

- **Age, years**:<br>  - <35 (n=61): 57%<br>  - 35 to <50 (n=101): 60%<br>  - ≥50 (n=110): 61%<br>  - Female (n=72): 63%<br>  - Male (n=200): 59%<br>  - White (n=185): 56%<br>  - Black or African American (n=68): 68%<br>  - North America (n=108): 58%<br>  - Europe (n=51): 55%<br>  - South America (n=105): 64%

- **Baseline HIV-1 RNA, copies/mL**:<br>  - ≥100,000 (n=80): 49%<br>  - 10,000 to <100,000 (n=117): 59%<br>  - 1000 to <10,000 (n=44): 73%<br>  - <1000 (n=31): 74%

- **Baseline CD4+ T-cell count, cells/mm³**:<br>  - <20 (n=72): 46%<br>  - 20 to <50 (n=25): 56%<br>  - 50 to <100 (n=39): 54%<br>  - 100 to <200 (n=63): 65%<br>  - ≥200 (n=73): 74%

- **Initial OBT**:<br>  - FAA: 65%<br>  - S-GSS: 62%<br>  - GSS: 56%

- **Initial OBT: PSS**:<br>  - >0 to 1 (n=20): 60%<br>  - >1 to 2 (n=130): 59%<br>  - >2 (n=112): 64%

- **Initial OBT: OSS**:<br>  - >0 to 1 (n=27): 52%<br>  - >1 to 2 (n=131): 59%<br>  - >2 (n=89): 66%

- **Initial OBT: OSS-new**:<br>  - 0 (n=35): 31%<br>  - >0 to 1 (n=105): 58%<br>  - >1 to 2 (n=101): 68%<br>  - >2 (n=17): 88%
#FAA, number of fully-active antiretrovirals according to study entry criteria; GSS, genotypic susceptibility score; PSS, phenotypic susceptibility score; OBT, optimized background therapy; OSS, overall susceptibility score; S-GSS, Stanford GSS. Only subgroups with ≥20 participants are shown. aResponse rates in other subgroups were American Indian/Alaskan Native: 57% (4/7), Native Hawaiian/Other Pacific Islander: 100% (1/1), Asian: 100% (2/2), and other: 71% (12/17). bResponse rate for rest of world was 88% (7/8). cResponse rate for #FAA = 0 was 31% (5/16). dResponse rates for S-GSS = 0 and missing were 100% (1/1) and 13% (1/8), respectively. eResponse rates for GSS = 0 and missing were 0% (0/1) and 11% (1/9), respectively. fResponse rate for PSS missing was 20% (2/10). gResponse rate for OSS missing was 47% (7/15). hResponse rate for OSS-new missing was 50% (7/14). iIncluded for comparison with other OBT susceptibility scores.